RedHill Biopharma is actively pursuing collaborations to advance opaganib, an investigational oral drug, as a treatment for the current Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus subtype. Opaganib has demonstrated significant antiviral activity, including a 70.2% mortality reduction in severe COVID-19 patients when added to standard care, and preclinical studies show it inhibits Ebola virus replication and improves survival in animal models. Its oral administration, ease of storage, and host-directed mechanism make it a promising candidate for rapid clinical evaluation and potential stockpiling, especially as the WHO warns the outbreak is outpacing response efforts. RedHill has provided safety, efficacy, and supply data to support quick regulatory and clinical discussions to address this urgent global health threat.
Gilead Sciences announced positive Phase 3 IDEAL study results for Livdelzi (seladelpar) in treating primary biliary cholangitis (PBC). The drug significantly normalized alkaline phosphatase (ALP), a critical liver disease marker, in patients with in...
In the first half of 2026, smart beta strategies showed mixed results, with momentum and low-volatility funds lagging, while dividend growth funds struggled due to rising yields. However, funds emphasizing companies with strong free cash flow and hig...
